Precision targeting of type 2 inflammation in COPD: identifying candidates for dupilumab therapy
Type 2 (T2) inflammation represents a clinically important and therapeutically tractable endotype in 20%–40% of patients with chronic obstructive pulmonary disease (COPD). This subgroup is characterised by elevated blood eosinophil counts, increased fractional exhaled nitric oxide (FeNO), and activation of the interleu...